CONTEMPORARY NATIONAL PATTERNS OF ELIGIBILITY AND UTILIZATION OF NOVEL CARDIOPROTECTIVE ANTI-HYPERGLYCEMIC AGENTS IN TYPE 2 DIABETES
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(21)02893-x
Abstract: Background Sodium glucose transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively lowered cardiovascular risk in large clinical trials for patients with type 2 diabetes at high risk for these complications, and have recommended… read more here.
Keywords: inhibitors glp; contemporary national; sglt inhibitors; type diabetes ... See more keywords
A Review of the Renoprotective Effects of Novel Antidiabetic Agents
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Pharmacy Practice"
DOI: 10.1177/0897190020902344
Abstract: The objective of this review article was to identify and examine current evidence surrounding the potential renoprotective effects of newer antidiabetic agents such as sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucose-like peptide 1 (GLP-1) agonists, and… read more here.
Keywords: review renoprotective; sglt inhibitors; renoprotective effects; inhibitors glp ... See more keywords
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "PLoS ONE"
DOI: 10.1371/journal.pone.0217701
Abstract: Background The last international consensus on the management of type 2 diabetes (T2D) recommends SGLT-2 inhibitors or GLP-1 agonists for patients with clinical cardiovascular (CV) disease; metformin remains the first-line glucose lowering medication. Last studies… read more here.
Keywords: risk; analysis; sglt inhibitors; mortality ... See more keywords
Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials.
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes care"
DOI: 10.2337/dc21-1722
Abstract: BACKGROUND Whether the cardiorenal benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) are comparable between White and Asian populations remains unclear. PURPOSE To compare the cardiorenal benefits of SGLT2… read more here.
Keywords: sglt2 inhibitors; asian white; white populations; inhibitors glp ... See more keywords